MetaVia Inc. (NASDAQ: MTVA)

NeuroBo Pharmaceuticals, Inc. (NRBO) is a clinical-stage biotechnology company operating in the healthcare industry, specifically focused on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company's primary business activities encompass research and development, preclinical developments, clinical trials, and raising capital. NeuroBo's operations span across various countries, including the United States.

The company generates revenue through the development and commercialization of its primary products, DA-1241 and DA-1726. DA-1241 is a G-Protein-Coupled Receptor 119 (GPR119) agonist, being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM). The company has completed Phase 1 clinical trials for DA-1241, demonstrating its potential to significantly reduce liver fat accumulation and inflammation. NeuroBo is currently conducting a Phase 2a trial for DA-1241, aiming to establish its mechanism of action and efficacy in treating MASH and T2DM.

DA-1726, on the other hand, is a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, being developed for the treatment of obesity. Preclinical studies for DA-1726 have shown promising results, indicating its effectiveness in reducing body weight and improving metabolic parameters. NeuroBo plans to initiate a Phase 1 clinical trial for DA-1726 in the first half of 2024.

NeuroBo holds a competitive edge in the cardiometabolic disease market, attributed to its focus on developing novel pharmaceuticals, experienced management team, and robust intellectual property portfolio. The company's key competitors include established entities such as Novo Nordisk, Eli Lilly, and Pfizer.

NeuroBo's customers include pharmaceutical companies, research institutions, and government agencies. The company's products are being developed for the treatment of various cardiometabolic diseases, including MASH, T2DM, and obesity. The company's product portfolio also includes ANA001, NB-01, NB-02, and Gemcabene, which are not being advanced to future clinical trials but are being considered for out-licensing and divestiture opportunities.